From the PBS science series NOVA, a biweekly podcast digging into the science behind the headlines. Alok Patel takes you behind the scenes with the people—scientists, engineers, technologists, mathematicians and more—working to understand our world. Now it's more critical than ever to distinguish fact from fiction and find science-based answers to the most pressing questions of our time.
Subscribe, and learn more by visiting pbs.org/novanowpodcast.
From the PBS science series NOVA, a biweekly podcast digging into the science behind the headlines. Alok Patel takes you behind the scenes with the people—scientists, engineers, technologists, mathematicians and more—working to understand our world. Now it's more critical than ever to distinguish fact from fiction and find science-based answers to the most pressing questions of our time.
Subscribe, and learn more by visiting pbs.org/novanowpodcast.
Pending FDA approval, safe and effective COVID-19 vaccines could reach the first wave of Americans in a matter of weeks. Manufacturers of leading vaccine candidates are releasing promising results from clinical trials, revealing that some experimental vaccines, including those from Pfizer and Moderna, are more than 90% effective against the coronavirus. But vaccine development alone will not end the pandemic; getting the distribution right is key. Host Alok Patel speaks with two immunization experts about the challenges of distribution at an unprecedented scale. Tune in to explore questions like: What are the differences between the first vaccine candidates? Who can expect to get vaccinated first and how much will it cost? And why do vaccines have to be kept so cold?